Guerbet S. A. (GBT) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Guerbet S. A. stock €19.35, price €6.45, upside +200.0%, quality 40 out of 100. Rating: strongly undervalued. Calculated from audited financials with 7 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range €5.81 – €40.47 · fair‑value band €8.84 – €32.35 · the €6.45 price screens below the €19.35 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow Guerbet S. A. in your weekly email
Every Wednesday you see whether Guerbet S. A. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Guerbet SA provides a range of contrast media, medical devices, and digital and AI solutions for diagnostic and interventional imaging worldwide.
Show moreShow less
It offers DOTAREM, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced MRI examinations; Elucirem, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced resonance imaging; UNIK, a diagnostic imaging interconnected solution; and Artirem, a gadoteric acid.
The company also provides OptiStar Elite, a dual head contrast delivery system with an ultrasonic motor; Ready-Box, a contrast media warmer; MRI accessories and consumables for diagnostic imaging; OptiProtect 3S, a suite of services and support solution; Conray/Cysto-Conray, an iothalamate meglumine injection contrast agent for CT; Micropaque/Microtrast, a barium sulfate contrast agent for CT; Optiray, an ioversol contrast agent for CT and Cath lab; Telebrix Gastro, a meglumine ioxitalamate contrast agent for CT; and Xenetix/ScanBag by Xenetix, an Iobitridol contrast agent for CT and Cath lab.
In addition, it offers OptiBolus, which allows for a uniform vascular enhancement throughout the procedure; OptiOne, a single head injector; OptiVantage Multi-use, an optimal power injector for X-ray procedures; OptiVantage, a dual-head CT contrast delivery injector; Illumena Néo, a multi-mode contrast delivery injector; Lipiodol Ultra Fluid, an iodinated ethyl ester of fatty acids of poppy seed oil; Qitexio, a range of lipiodol resistant medical devices consisting of medical syringes and a stopcock; Lipiodol Ultra Fluid for use in interventional radiology and women's health; and Patent Blue V, a pharmaceutical drug for breast cancer.
The company was founded in 1901 and is headquartered in Villepinte, France.
Stock analysis
Guerbet S. A. (GBT) currently trades at €6.45, while our model-based Fair Value estimate is €19.35, implying the stock looks roughly 67% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of €43.73 per share, and 6 of the 7 models we run sit above the €6.45 price.
Bear case: the Asset-Based group reads lowest at €10.97, and 1 of the 7 models stay below the price. Data coverage for this calculation is low.
Scenario range: €8.84 (bear) to €32.35 (bull), the price of €6.45 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Guerbet S. A. reported revenue of €786M in FY2025 versus €736M in FY2021, a compound +1.7%/yr. Reported net income was −€108M in FY2025.
Key figures
Market cap €81.5M Micro · P/S ratio 0.09 · EPS (TTM) €−11.46 · Dividend yield 8.4% · Net margin −17.8% · Return on equity −48.4% · Return on assets (EBIT) 3.0% (5-year average) · Operating margin −4.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).
What moves the price
The share trades about 64% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at 200%, GBT screens cheaper than that median.
Fair Value models
Bear€8.84Fair Value €19.35Bull€32.35
Price €6.45 · Upside +200.0%
Capped: our models arrive at a very high value here. We deliberately show a more cautious Fair Value.
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.28/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−7.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.0%
Start year 2020 (pandemic). Over 10 years: +4.8% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.7%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
4.9% (2020) → 0.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+8.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+2.7%
Yearly sales growth analysts expect, extended to five years.
After inflation (euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about +6.4% a year for the price and +0.5% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (73 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 318 stocks
Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score40 · Bottom 25%
Fair Value upside+200.0% · Top 25%
Profitability
Return on assets−11.7% · Bottom 25%
Net margin (12 months)−17.8% · Bottom 25%
Operating margin (12 months)−4.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−2.0% · Bottom 25%
Dividend yield (12 months)8.4% · Top 25%
Balance sheet
Debt / equity1.43× · Highest 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Guerbet S. A. Fair Value". https://www.fairvalue-calculator.com/stock/GBT.PA
Frequently asked questions
Is Guerbet S. A. (GBT) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of €19.35 versus a price of €6.45, about +200% upside (undervalued).
What is the fair value of GBT?
Our model-based fair value for Guerbet S. A. is €19.35 (as of Nov 9, 2026), built from audited fundamentals. The current price: €6.45.
What is the quality score of GBT?
Guerbet S. A. has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Guerbet S. A. (GBT)?
Our model-based price target is the fair value of €19.35 (as of Nov 9, 2026) from 7 valuation models. Cautious scenario €8.84, optimistic scenario €32.35. It is a calculation from audited fundamentals, not an analyst target.
What is the Guerbet S. A. stock forecast for 2026?
Our models put fair value at €19.35, about +200% upside versus a price of €6.45 (undervalued). Cautious scenario €8.84, optimistic scenario €32.35. The calculation is refreshed regularly with new filings.
What is the revenue of Guerbet S. A. (GBT)?
Guerbet S. A. reported trailing-twelve-month revenue of about €791M (latest available figure, as of Nov 9, 2026).
Does Guerbet S. A. pay a dividend?
Guerbet S. A. currently shows a dividend yield of 8.40% relative to its recent price (as of Nov 9, 2026).
How much is the dividend of Guerbet S. A. (GBT)?
Guerbet S. A. has a dividend yield of 8.4%.
What growth is priced into Guerbet S. A. (GBT)?
For today's price to be fair in a discounted-cash-flow model, Guerbet S. A. would have to grow free cash flow by +8.7 % per year for five years (discount rate 13.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +2.0 % per year. As of Nov 9, 2026.
What discount rate (WACC) does the fair value of GBT use?
Our models discount Guerbet S. A. at 13.5 %: a base by market capitalisation (micro), damped by beta 1.07, country premium for France. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Guerbet S. A. that is +8.7 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (13.5 %) and the same formula as our fair value.
How much growth has Guerbet S. A. (GBT) delivered so far?
Over the past 5 years revenue at Guerbet S. A. grew +2.0 % a year. The price currently implies free-cash-flow growth of +8.7 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Guerbet S. A. (GBT) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Guerbet S. A. (+8.7 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Guerbet S. A. (GBT)?
The free-cash-flow yield on the price is 38.54 %: that much free cash flow Guerbet S. A. produces per unit of market value. When it exceeds the discount rate of our models (13.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Guerbet S. A. (GBT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Guerbet S. A. it is €19.35 per share (as of Nov 9, 2026), against a price of €6.45. It is the blended result of 7 valuation models in 4 families (DCF Models, Multiples, Asset-Based, Growth DCF).
Is Guerbet S. A. stock overvalued or undervalued in 2026?
As of Nov 9, 2026, GBT trades below its calculated fair value: price €6.45, fair value €19.35, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GBT?
No. The price is what the market pays today (€6.45); the fair value is what the company's own numbers justify (€19.35). For Guerbet S. A. the two are €12.90 per share apart. That gap is exactly why we show both numbers side by side.
How much is Guerbet S. A. worth?
The market values Guerbet S. A. at about €81.5M (market capitalisation, as of Nov 9, 2026). Per share that is €6.45; our models calculate a fair value of €19.35 per share.
What do the bullish and bearish scenarios say about GBT?
Our models span a range for Guerbet S. A.: cautious scenario €8.84, base €19.35, optimistic €32.35 per share (as of Nov 9, 2026, price €6.45). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of GBT?
The PEG ratio of Guerbet S. A. is 0.07 (P/E divided by earnings growth, as of Nov 9, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Guerbet S. A. (GBT)?
Balance-sheet figures for Guerbet S. A. (as of Nov 9, 2026): return on equity −48.4%, debt of 1.43 per unit of equity. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is GBT from its 52-week high?
Guerbet S. A. trades at €6.45, about 64% below its 52-week high of €18.02 and 11% above the low of €5.81 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of €19.35 is for.
Which stocks are comparable to Guerbet S. A.?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Guerbet S. A. stock attractive at the current price?
The data as of Nov 9, 2026: price €6.45, calculated fair value €19.35 (+200%), Quality Score 40/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of GBT calculated?
We run Guerbet S. A. through 7 models from 4 families: DCF Models, Multiples, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of €19.35 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Guerbet S. A. currently trades 67% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Guerbet S. A. (GBT)?
The closing price on Nov 6, 2026 was €6.45. Our model-based fair value is €19.35, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Guerbet S. A. right now?
The large discount to fair value meets weak quality (40/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (€8.84). The market is more pessimistic than our downside scenario. The model range is unusually wide (€8.84 to €32.35). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Where does the earnings growth of Guerbet S. A. (GBT) come from?
Earnings per share at Guerbet S. A. grew −5.2 % a year from 2014 to 2025. Broken into its drivers: revenue per share +4.7 %, EBIT margin −7.1 %, tax rate +2.4 %, residual (interest, one-offs) −4.8 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Guerbet S. A.
How large is the market capitalisation of Guerbet S. A. (GBT)?
The market capitalisation of Guerbet S. A. is €81.5M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Guerbet S. A. (GBT)?
The price-to-sales ratio of Guerbet S. A. is 0.09 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Guerbet S. A. (GBT)?
Earnings per share at Guerbet S. A. are €−11.46. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Guerbet S. A. (GBT)?
The dividend yield of Guerbet S. A. is 8.4%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Guerbet S. A. (GBT)?
The net margin of Guerbet S. A. is −17.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Guerbet S. A. (GBT)?
The return on equity (ROE) of Guerbet S. A. is −48.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Guerbet S. A. (GBT)?
On an EBIT basis the return on assets of Guerbet S. A. is 3.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Guerbet S. A. (GBT)?
The operating margin of Guerbet S. A. is −4.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Guerbet S. A. (GBT)?
Revenue at Guerbet S. A. is growing −2.0% versus a year earlier (3y avg +0.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Guerbet S. A. (GBT)?
Earnings per share at Guerbet S. A. are growing −75.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Guerbet S. A. (GBT) carry?
The net debt of Guerbet S. A. is €322M (fiscal year 2025, ≈ 10.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Guerbet S. A. in the live analysis
One click puts Guerbet S. A. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 9, 2026